104206-65-7 | 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$7.00	$5.00
10mg	98%	in stock	$9.00	$6.00
50mg	98%	in stock	$15.00	$11.00
250mg	98%	in stock	$26.00	$18.00
1g	98%	in stock	$51.00	$36.00
5g	98%	in stock	$173.00	$121.00
10g	98%	in stock	$286.00	$201.00
25g	98%	in stock	$690.00	$483.00
100g	98%	in stock	$2,143.00	$1,500.00

Description

• Catalog Number: AB58940
• Chemical Name: 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
• CAS Number: 104206-65-7
• Molecular Formula: C14H10F3NO5
• Molecular Weight: 329.2281
• MDL Number: MFCD01752192
• SMILES: O=C1CCCC(=O)C1C(=O)c1ccc(cc1[N+](=O)[O-])C(F)(F)F

Computed Properties

• Complexity: 524
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 23
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 2
• XLogP3: 2.3

Literature

• Single dose NTBC-treatment of hereditary tyrosinemia type I.

  Journal of inherited metabolic disease 20120901

• Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.

  Molecular genetics and metabolism 20120901

• Focal ligamentum flavum hypertrophy with ochronotic deposits: an unusual cause for neurogenic claudication in alkaptonuria.

  Asian spine journal 20120601

• Simple and fast quantification of nitisone (NTBC) using liquid chromatography-tandem mass spectrometry method in plasma of tyrosinemia type 1 patients.

  Journal of chromatographic science 20120501

• Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?

  Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 20120401

• Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC.

  Journal of inherited metabolic disease 20120301

• [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].

  Revista medica de Chile 20120201

• LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.

  Analytical chemistry 20120117

• A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems.

  Journal of inherited metabolic disease 20111201

• Natural history of alkaptonuria revisited: analyses based on scoring systems.

  Journal of inherited metabolic disease 20111201

• Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.

  Pediatrics international : official journal of the Japan Pediatric Society 20111201

• Alkaptonuria: treasure your exceptions.

  Journal of inherited metabolic disease 20111201

• Medical management of chronic liver diseases in children (part I): focus on curable or potentially curable diseases.

  Paediatric drugs 20111201

• Grown up mice from gene-corrected iPS cells.

  Circulation research 20111111

• Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinism.

  The Journal of clinical investigation 20111003

• Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.

  The Journal of clinical investigation 20111003

• Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.

  Developmental medicine and child neurology 20111001

• Long-term outcome of living donor liver transplantation in a Thai boy with hereditary tyrosinemia type I: a case report.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20111001

• A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.

  Molecular genetics and metabolism 20110801

• Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases.

  World journal of pediatrics : WJP 20110801

• Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.

  PLoS biology 20110701

• Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110401

• Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.

  Molecular genetics and metabolism 20110201

• Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).

  Clinica chimica acta; international journal of clinical chemistry 20110114

• Alkaptonuria.

  Indian journal of dermatology 20110101

• A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.

  Clinical and experimental rheumatology 20110101

• Hepatic differentiation of murine disease-specific induced pluripotent stem cells allows disease modelling in vitro.

  Stem cells international 20110101

• Alkaptonuria.

  Dermatology online journal 20101115

• A late and difficult diagnosis of ochronosis.

  Journal of medicine and life 20101115

• Product analysis and inhibition studies of a causative Asn to Ser variant of 4-hydroxyphenylpyruvate dioxygenase suggest a simple route to the treatment of Hawkinsinuria.

  Biochemistry 20100824

• Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.

  Pediatrics 20100701

• Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?

  European journal of pediatrics 20100601

• Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1.

  European journal of pediatrics 20100501

• High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.

  Journal of gastroenterology and hepatology 20100501

• Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis.

  Talanta 20100315

• Identification of NTBC metabolites in urine from patients with hereditary tyrosinemia type 1 using two different mass spectrometric platforms: triple stage quadrupole and LTQ-Orbitrap.

  Rapid communications in mass spectrometry : RCM 20100301

• A metabolic cause of spinal deformity.

  Metabolism: clinical and experimental 20100101

• [Clinical, biochemical and molecular characteristics in 11 Czech children with tyrosinemia type I].

  Casopis lekaru ceskych 20100101

• Persistent coagulopathy during Escherichia coli sepsis in a previously healthy infant revealed undiagnosed tyrosinaemia type 1.

  BMJ case reports 20100101

• Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090515

• Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.

  Acta biochimica Polonica 20090101

• No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study.

  Orphanet journal of rare diseases 20090101

• A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.

  Orphanet journal of rare diseases 20090101

• Ochronosis of hip joint; a case report.

  Cases journal 20090101

• Ochronosis as an unusual cause of valvular defect: a case report.

  Journal of medical case reports 20090101

• Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.

  Journal of inherited metabolic disease 20081201

• Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development.

  Hepatology (Baltimore, Md.) 20080801

• Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis.

  Cancer cell 20080708

• Renal tubular function in children with tyrosinaemia type I treated with nitisinone.

  Journal of inherited metabolic disease 20080601

• Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.

  Expert opinion on pharmacotherapy 20080501

• Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment.

  Molecular genetics and metabolism 20080301

• Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.

  Journal of hepatology 20080201

• NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.

  Journal of inherited metabolic disease 20080201

• Alkaptonuria diagnosed in a 4-month-old baby girl: a case report.

  Cases journal 20080101

• Identification of 2-[2-nitro-4-(trifluoromethyl)benzoyl]- cyclohexane-1,3-dione metabolites in urine of patients suffering from tyrosinemia type I with the use of 1H and 19F NMR spectroscopy.

  Acta biochimica Polonica 20080101

• Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I.

  Molecular therapy : the journal of the American Society of Gene Therapy 20070701

• Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.

  Prescrire international 20070401

• In silico prediction of pregnane X receptor activators by machine learning approaches.

  Molecular pharmacology 20070101

• Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?

  Molecular genetics and metabolism 20061201

• [New drugs; nitisinone].

  Nederlands tijdschrift voor geneeskunde 20061118

• Harnessing a high cargo-capacity transposon for genetic applications in vertebrates.

  PLoS genetics 20061101

• Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury.

  Toxicology and applied pharmacology 20060815

• Lectin-reactive alpha-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma.

  Journal of pediatric gastroenterology and nutrition 20060701

• Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.

  Biochemical pharmacology 20060528

• The genetic tyrosinemias.

  American journal of medical genetics. Part C, Seminars in medical genetics 20060515

• Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.

  Molecular genetics and metabolism 20060501

• Response of metastatic recurrent neuroblastoma to nitisinone: a modulator of tyrosine metabolism.

  Pediatric blood & cancer 20060401

• Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I.

  The Journal of biological chemistry 20060303

• Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.

  Pediatric research 20060301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060301

• Cardiomyopathy in tyrosinaemia type I is common but usually benign.

  Journal of inherited metabolic disease 20060201

• Current strategies for the treatment of hereditary tyrosinemia type I.

  Paediatric drugs 20060101

• Nitisinone in the treatment of hereditary tyrosinaemia type 1.

  Drugs 20060101

• Drug discovery from medicinal plants.

  Life sciences 20051222

• Spectroscopic and computational studies of NTBC bound to the non-heme iron enzyme (4-hydroxyphenyl)pyruvate dioxygenase: active site contributions to drug inhibition.

  Biochemical and biophysical research communications 20051209

• Transcriptome analysis of Paracoccidioides brasiliensis cells undergoing mycelium-to-yeast transition.

  Eukaryotic cell 20051201

• Use of nitisinone in patients with alkaptonuria.

  Metabolism: clinical and experimental 20050601

• Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia.

  Analytical biochemistry 20050415

• New developments in ochronosis: review of the literature.

  Rheumatology international 20050301

• Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I.

  Journal of inherited metabolic disease 20050101

• [Lectin-reactive alpha-fetoprotein in tyrosinaemia type I].

  Klinische Padiatrie 20050101

• Hepatomegaly: commentary.

  Clinical pediatrics 20050101

• Liquid chromatography-tandem mass spectrometry method for the simultaneous determination of delta-ALA, tyrosine and creatinine in biological fluids.

  Clinica chimica acta; international journal of clinical chemistry 20041201

• Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review.

  Clinical medicine & research 20041101

• D-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism.

  Toxicology 20040901

• Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.

  Kidney international 20040901

• Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.

  Annals of tropical paediatrics 20040901

• Structure of the ferrous form of (4-hydroxyphenyl)pyruvate dioxygenase from Streptomyces avermitilis in complex with the therapeutic herbicide, NTBC.

  Biochemistry 20040601

• Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.

  Hepatology (Baltimore, Md.) 20040201

• Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).

  Journal of hepatology 20031201

• 4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target.

  Drug news & perspectives 20031001

• Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.

  Biochemistry 20030902

• Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress.

  Free radical biology & medicine 20030815

• Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.

  Acta paediatrica (Oslo, Norway : 1992) 20030501

• The role of mode of action studies in extrapolating to human risks in toxicology.

  Toxicology letters 20030411

• Alkaptonuria.

  The New England journal of medicine 20030403

• Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

  Journal of inherited metabolic disease 20030101

• Natural history of alkaptonuria.

  The New England journal of medicine 20021226

• Goldenhar syndrome and hereditary tyrosinemia type 1.

  Saudi medical journal 20021201

• Corneal opacities associated with NTBC treatment.

  American journal of ophthalmology 20020801

• Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.

  Journal of pediatric gastroenterology and nutrition 20020701

• From the Food and Drug Administration.

  JAMA 20020306

• Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.

  Molecular genetics and metabolism 20020101

• Drug to treat rare pediatric liver disease.

  FDA consumer 20020101

• Nitisinone. Ntbc, Orfadin.

  Drugs in R&D 20020101

• Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.

  British journal of clinical pharmacology 20010801

• [Evolution of a case of tyrosinemia type I treated with NTBC].

  Anales espanoles de pediatria 20010301

• SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase.

  Bioorganic & medicinal chemistry letters 20000501